Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560)
Binds DNA as a homodimer. Can form a heterodimer with ESR1. Interacts with NCOA1, NCOA3, NCOA5 and NCOA6 coactivators, leading to a strong increase of transcription of target genes.
Interacts with UBE1C. Interacts with AKAP13. Interacts with DNTTIP2.
Interacts with isoform 4 of TXNRD1. Interacts with CCDC62 in the presence of estradiol/E2; this interaction seems to enhance the transcription of target genes, including cyclin-D1/CCND1 AP-1 promoter. Interacts with DNAAF4 (By similarity).
Interacts with PRMT2. Interacts with CCAR2 (via N-terminus) in a ligand-independent manner. Interacts with RBM39, in the presence of estradiol (E2) (By similarity).
Interacts with STUB1/CHIP (By similarity)
Preferentially forms a heterodimer with ESR1 rather than ESR2 isoform 1 and inhibits DNA-binding by ESR1
Expressed in testis and ovary, and at a lower level in heart, brain, placenta, liver, skeletal muscle, spleen, thymus, prostate, colon, bone marrow, mammary gland and uterus. Also found in uterine bone, breast, and ovarian tumor cell lines, but not in colon and liver tumors
Expressed in spleen, thymus, testis and ovary and at a lower level in skeletal muscle, prostate, colon, small intestine, leukocytes, bone marrow, mammary gland and uterus
Expressed in the testis
Expressed in testis, and at a lower level in spleen, thymus, ovary, mammary gland and uterus
Expressed in testis, placenta, skeletal muscle, spleen and leukocytes, and at a lower level in heart, lung, liver, kidney, pancreas, thymus, prostate, colon, small intestine, bone marrow, mammary gland and uterus. Not expressed in brain
Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain
An autosomal dominant form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads.
No mutation information available.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to ESR2, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 10
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT02089854 | Female Breast Cancer | Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer | PHASE4 | UNKNOWN |
| NCT02062489 | Breast Cancer | Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients | PHASE3 | RECRUITING |
| NCT01723917 | Hot Flashes, Memory Loss | Phytoserms for Menopause Symptoms and Age-Associated Memory Decline | NA | COMPLETED |
| NCT02640976 | Infertility | Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program | EARLY_PHASE1 | COMPLETED |
| NCT03941730 | Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer | PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT05741060 | Arterial Stiffness, White Matter Lesions, Cognitive Decline | Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers | PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT01402648 | Adenocarcinoma of Colon Recurrent | Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence | PHASE1, PHASE2 | COMPLETED |
| NCT03689543 | Perimenopause-Related Depression | Estrogen Receptor Beta and Mood | PHASE2 | COMPLETED |
| NCT01874756 | Schizophrenia | The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia | PHASE2 | TERMINATED |
| NCT00799708 | Postmenopause | A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED) | PHASE1 | COMPLETED |